- FSD Pharma, SciCann Launch clinical research program in Israel
- Eisai, Merck get FDA approval for LENVIMA capsules to treat HCC
- Scientists develop platform to kill cancer cells
- Shanghai ChemPartner closes deal with Quantum
- Medtronic introduces IN.PACT Admiral DCB in Japan
- Blueberry Therapeutics raises £10M funding to develop nanomedicines
- Dr Sundar receives an honor of first female President of BGCS
- Bugworks Research raises $9M in series A funding
- rfxcel enhances Pharmaceutical Track and Trace Solution for Russia
- Merck receives Australian CRISPR Nickase Patent
- Mundipharma brings cancer supportive care expertise to Vietnam
- Middle East, Africa pharma economy to reach $38.8B by 2021
- Multi- institutional alliance to develop anti-aging drugs
- Crown Bioscience to expand GEM selection through new collaboration
-
Pharma | 05 January 2018 | News
AstraZeneca collaborates with Myriad Genetics for cancer therapy
AstraZeneca is working in collaboration with the molecular diagnostics firm Myriad Genetics’ for its tes...Read more
Digital Health | 05 January 2018 | News
Microsoft partners with Adaptive Biotechnologies
The tech giant Microsoft is partnering with Seattle biotech company Adaptive Biotechnologies on a year-long pr...Read more
-
Japan | 17 August 2018 | News
Eisai, Merck get FDA approval for LENVIMA capsules to treat HCC
Eisai Inc. and Merck known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Ad...Read more
-
Australia | 16 August 2018 | News
Merck receives Australian CRISPR Nickase Patent
Merck, the vibrant science and technology company has announced that the Australian Patent Office has allowed ...Read more
-
Japan | 17 August 2018 | News
Medtronic introduces IN.PACT Admiral DCB in Japan
Dublin-based Medtronic has announced the commercial launch of the IN.PACT Admiral Drug-Coated Balloon (DCB) in...Read more
-
Pharma | 04 January 2018 | News
Europe's biggest private biotech company raises $270 million
Europe’s largest privately held biotech company, Germany-based BioNTech, has raised $270 million to supp...Read more
Accelerating IVD Innovations
Not always perceived as the most exciting field as therapeutics, the diagnostics industry is gaining momentum and growing and changing just as fast. At a rapid pace with projected sales growth between 2012 and 2018 from $43.6 billion to $58.8 billion (CAGR of 5.1 per cent), the industry looks appealing (EvaluateMedtech). Despite global economic and industry challenges, in-vitro diagnostics (IVD) markets are growing robustly at double the rate of the global pharmaceutical industry in some segments. Growth in emerging markets and next-wave emerging markets, particularly in the Asia-Pacific (APAC) region, are the most important factors in formulating future strategies.
